MS Drugs Ocrevus, Kesimpta, and Lemtrada Remain Subsidised

Health Minister Mark Butler confirms that Ocrevus, Kesimpta, and Lemtrada will remain subsidised under the Pharmaceutical Benefits Scheme, ensuring continued access for Australians with multiple sclerosis. This decision follows concerns raised by the drug manufacturers about potential removal from the scheme.

Read the full story at The Guardian AU→